anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain an anti-osteoporosis agent having a suppressive function against osteoclast formation and excellent in activity and safety by compounding a polyisoprenoide derivative as an effective component. CONSTITUTION:This agent contains a compound of formula I (R is OH, formula II or formula III; waved line is an E-type or a Z-type double bond), e.g. (2E,6E,10 E)-3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraene-1-ol. The agent may be formulated into a preparation, e.g. a powder, a particle, a granule, a tablet, a coated tablet, a capsule, an ointment, a plaster or an injection. A daily dose for an adult is 100-3000mg. The compound of formula I has the suppressive activity against osteoclast formation in a coexistent system of an osteoblast and a spleen cell. In osteoporosis, the balance between bone resorption and osteogenesis is destroyed and the bone resorption is accelerated. As a result, the amount of bone is decreased, bones become fragile and pain is accompanied. Osteoporosis frequently occurs especially in a postmenopausal woman and its treatment continues for a long time. Therefore, the danger of the occurrence of side effects characteristic to female sex hormones is concerned and so as drug is required to have high safety.
The invention discloses a bottle gourd essence lotion, which comprises the following components in weight percentage: 80-95 percent of purely natural and fresh collected bottle gourd lotion and 5-20 percent of coarse salt (iodine-containing low-sodium coarse-particle salt), wherein the weight percentage of the coarse salt is 5-10 percent preferably, the sum of the weight percentage of all the components is 100 percent, and the pH value is 7.5-8.0. The bottle gourd lotion is reasonable in structure and good in health-care effect, can be easily processed and manufactured, has no toxic and side effects after being used for a long time, is safe and reliable and can be used for reducing the dependence on other hormone drugs. By often using the bottle gourd essence lotion, a pretty good anti-inflammation and antipruritic effect can be performed on facial acnes, whelks, skin itching, crissum itching and external genitalia itching which are caused by seasonal variations, piles, nameless pyogenic infections and pimples and galls caused by getting angry. Meanwhile, a very good anti-inflammation, antipruritic and analgesic effect can be performed on burn itching, scald itching, cut itching, finger seam peeling itching, nail seam peeling itching, dermatophytosis itching, sandworm foot peeling and dampness itching, whereas scars are not left. Proved by practice, the bottle gourd essence lotion is most efficient on symptoms, such as the acnes, the whelks and the pimples and galls by using a method of massage combined with face towel wet compressing, and the bottle gourd essence lotion can take effect after being used for 5-7 times a day. Moreover, the bottle gourd essence lotion is good in use feeling and convenient in carrying and use and can be widely used for human body health care and daily life.
The present disclosure provides glass compositions that include from about 20 mol% to 45 mol% of B2O3; and from about 10 mol% to about 80 mol% of one or more glass components selected from the group consisting of CaO and MgO. The glass compositions also include less than 0.1 mol% CdO. The glass compositions may include one or more of Na2O, K2O, and a phosphate source, where the B2O3 and the phosphate source total about 60 mol% or less. The glass compositions may include a source of fluoride. The glass composition may be used to desensitize dentin. The present disclosure also provides dentin-desensitizing compositions, as well as methods and uses of the disclosed glass compositions.
PURPOSE: A cosmetic composition of skin regeneration, anti-inflammatory, and skin suppression and a manufacturing method thereof are provided to have excellent anti-inflammatory effect, moisturizing, whitening, skin calming, skin regenerating, or anti-wrinkle by including a leech extract, placenta extract and a ginseng extract. CONSTITUTION: A cosmetic composition of skin regeneration, anti-inflammatory and skin suppression comprises leech extract, placenta extract and ginseng extract. The leech extract, placenta extract and ginseng extract are included in a weight ratio of 5-15:1-10:1-5. The leech extract is Hirudo medicinalis extract. The placenta extract is a pig placenta fermentation extract obtained by fermenting pig placenta. The pig placenta fermentation extract is obtained by processing Nano liposome after processing pig placenta a first fermentation with a Bacillus strain and a second fermentation with an Aspergillus virus. [Reference numerals] (AA) Embodiment 1; (BB) Comparative embodiment 4
Disclosed are a hyaluronic acid-based amphiphilic polymer, preparation method and application thereof. A main chain of the amphiphilic polymer is a hydrophilic hyaluronic acid and can be employed in active targeting, and a side chain thereof is a hydrophobic group represented by Formula (1). The amphiphilic polymer can carry a small molecule anticancer drug. Polymer nanoparticles are obtained via chemical crosslinking, such that the nanoparticles are not readily dissociated outside a cell or in blood, thus ensuring the stability of a drug encapsulated by the nanoparticles. Upon arriving at a tumor tissue, the hyaluronic acid on a surface of the nanoparticle can immediately combine with a CD44 receptor on a surface of a tumor cell, and effectively enter the tumor cell via endocytosis mediated by the receptor, and then quickly de-crosslink to be dissociated. The drug is quickly released, obtaining an enrichment ratio at a tumor site markedly higher than that of the prior art, resulting in a highly effective treatment, and addressing deficiencies such as drug leakage, low carrying efficiency, low occurrence of endocytosis and slow release in a cell.
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) occurs in the jawbone and interfacing oral mucosa of patients treated with bisphosphonates. Herein, we report novel histopathological findings in the oral mucosa of a surgical specimen obtained from a 61-year-old man with BRONJ. The resected jawbone and adjacent oral mucosa were separated for histological examination. The mucosal tissue was examined using Von Kossa staining and immunohistochemical (CK5/6, p63) staining of non-decalcified paraffin sections. Pseudoepitheliomatous hyperplasia (PEH), a microscopic feature of the mucosal epithelium in BRONJ, was observed in soft tissue specimens, concomitant with inflammatory cell infiltration. Von Kossa staining revealed small fragments of necrotic bone, tens to hundreds of micrometers in size, scattered within the connective tissues; the PEH forefront contacted some of the bone fragments. Immunohistochemical staining demonstrated that occasionally, the PEH not only contacted but also encompassed the bone fragments. To our knowledge, this is the first report of presence of micro bone fragments and their association with PEH in the oral mucosa in BRONJ.
The intelligent cardiopulmonary rehabilitation system is designed to improve the user's adherence to pre-determined training intensity. The training intensity is pre-determined using the 60%-80% heart rate reserve which is obtained from the cardiopulmonary exercise test at prestest. The system allows dynamically auto-adjust the paddling resistance in accordance to the patient's current hear rate and paddling rate, with the goal to maintain the patient's heart rate at the pre-determined heart rate zone through the training period.
Biallelic pathogenic variants in the TTC26 gene are known to cause BRENS (biliary, renal, neurological, skeletal) syndrome, an ultra-rare autosomal recessive condition with only few patients published to date. BRENS syndrome is characterized by hexadactyly, severe neonatal cholestasis, and involvement of the brain, heart, and kidney, however the full phenotypic and genotypic spectrum is unknown. Here, we report on a previously undescribed homozygous intronic TTC26 variant (c.1006-5 T > C) in a patient showing some of the known TTC26-associated features like hexadactyly, hypopituitarism, hepatopathy, nephropathy, and congenital heart defect. Moreover, he presented with a suspected unilateral hearing loss and bilateral cleft lip-palate. The variant is considered to affect correct splicing by the loss of the canonical acceptor splice site and activation of a cryptic acceptor splice site. Hereby, our patient represents one additional patient with BRENS syndrome carrying a previously unreported TTC26 variant. Furthermore, we confirm the involvement of the pituitary gland to be a common clinical feature of the syndrome and broaden the clinical spectrum of TTC26 ciliopathy to include facial clefts and a probable hearing involvement.
AIMS: Hereditary transthyretin amyloidosis (ATTRv) is one of the leading aetiologies of systemic amyloidosis with more than 135 mutations described and a broad spectrum of clinical manifestations. We aimed to provide a systematic description of a population of individuals carrying pathogenic mutations of transthyretin (TTR) gene and to investigate the major clinical events during follow-up.
METHODS AND RESULTS: This was an observational, retrospective, cohort study including consecutive patients with mutations of TTR gene, admitted to a tertiary referral centre in Bologna, Italy, between 1984 and 2022. Three hundred twenty-five patients were included: 106 asymptomatic carriers, 49 cardiac phenotype, 49 neurological phenotype, and 121 mixed phenotype. Twenty-two different mutations were found, with Ile68Leu (41.8%), Val30Met (19%), and Glu89Gln (10%) being the most common. After a median follow-up of 51 months, 111 patients (38.3%) died and 9 (11.5%) of the 78 asymptomatic carriers developed ATTRv. Carriers had a prognosis comparable with healthy population, while no significant differences were seen among the three phenotypes adjusted by age. Age at diagnosis, New York Heart Association class III, left ventricular ejection fraction, modified polyneuropathy disability score IV, and disease-modifying therapy were independently associated with survival.
CONCLUSION: This study offers a wide and comprehensive overview of ATTRv from the point of view of a tertiary referral centre in Italy. Three main phenotypes can be identified (cardiac, neurological, and mixed) with specific clinical and instrumental features. Family screening programmes are essential to identify paucisymptomatic affected patients or unaffected carriers of the mutation, to be followed through the years. Lastly, disease-modifying therapy represents an evolving cornerstone of the management of ATTRv, with a great impact on mortality.
Administer with caution to elderly people; to those with cardiovascular disease, hypertension, diabetes, or hyperthyroidism; in psychoneurotic individuals; and in pregnancy.

Patients with long-standing bronchial asthma and emphysema who have developed degenerative heart disease should be administered the drug with extreme caution.

Overdosage or inadvertent intravenous injection of epinephrine may cause cerebrovascular hemorrhage resulting from the sharp rise in blood pressure.

Fatalities may also result from pulmonary edema because of the peripheral constriction and cardiac stimulation produced. Rapidly acting vasodilators, such as nitrites, or alpha blocking agents may counteract the marked pressor effects of epinephrine.

Epinephrine is the preferred treatment of serious allergic or other emergency situations even though this product contains sodium metabisulfite, a sulfite that may in other products cause allergic-type reactions including anaphylactic symptoms or life-threatening or less severe asthmatic episodes in certain susceptible persons. The alternative to using epinephrine in a life-threatening situation may not be satisfactory. The presence of a sulfite in this product should not deter administration of the drug for treatment of serious allergic or other emergency situations.
The study will consist of two groups: Group Comparison (GC) will be submitted to two evaluations at the beginning of a week and end of 6 weeks, without receiving any kind of physical training intervention. Group Training (GT) will undergo two assessments at the beginning of the end of the 1st and 6th week, however will be submitted to aerobic training for six weeks. Supervised aerobic training will be held three times a week for six weeks,treadmill in four consecutive steps each (05 minutes stretching, 05 minutes heating, 20 training minutes (1 st and 2 nd week) and 30 minutes (3 rd to 6 weeks) and cool down 05 minutes). The exercise intensity will be maintained through a desired percentage of heart rate for training (x%) from 70% to 80%, obtaining then the optimal heart rate training.
A 67-year-old man visited our hospital for epigastric pain. Esophagogastroduodenoscopy(EGD)revealed type 2 gastric cancer from the cardia to the gastric angle, and histopathological examination revealed papillary adenocarcinoma(pap), HER2-positive. Contrast-enhanced CT showed wall thickening mainly in the posterior wall of the gastric body, enlarged lymph nodes that were lumped together with the main lesion, and 8 low-absorption areas with ring shaped contrast effects in both lobes of the liver. The patient was diagnosed as gastric cancer cT4aN(+)M1[HEP], clinical Stage ⅣB. Six courses of capecitabine plus cisplatin plus trastuzumab(XP plus Tmab)therapy and 17 courses of capecitabine plus trastuzumab(X plus Tmab)therapy were performed. After chemotherapy, liver and lymph node metastases disappeared on CT and MRI. EGD showed residual gastric cancer, and the policy was to resect the primary tumor. Laparoscopic total gastrectomy with D2 lymph node dissection was performed. Pathological results showed T1b(SM)depth, no lymph node metastasis, and histologic response was Grade 2a. Six courses of X plus Tmab were administered as postoperative adjuvant chemotherapy, but were discontinued at the patient's request. Currently, 5 years have passed since the first chemotherapy and 3.5 years have passed since the surgery, and the patient is alive without recurrence, suggesting that the conversion surgery may have contributed to the prolonged survival.
There are recognized neuroimaging regions of interest in typical Alzheimer's disease which have been used to track disease progression and aid prognostication. However, there is a need for validated baseline imaging markers to predict clinical decline in atypical Alzheimer's Disease. We aimed to address this need by producing models from baseline imaging features using penalized regression and evaluating their predictive performance on various clinical measures. Baseline multimodal imaging data, in combination with clinical testing data at two time points from 46 atypical Alzheimer's Disease patients with a diagnosis of logopenic progressive aphasia (N = 24) or posterior cortical atrophy (N = 22), were used to generate our models. An additional 15 patients (logopenic progressive aphasia = 7, posterior cortical atrophy = 8), whose data were not used in our original analysis, were used to test our models. Patients underwent MRI, FDG-PET and Tau-PET imaging and a full neurologic battery at two time points. The Schaefer functional atlas was used to extract network-based and regional gray matter volume or PET SUVR values from baseline imaging. Penalized regression (Elastic Net) was used to create models to predict scores on testing at Time 2 while controlling for baseline performance, education, age, and sex. In addition, we created models using clinical or Meta Region of Interested (ROI) data to serve as comparisons. We found the degree of baseline involvement on neuroimaging was predictive of future performance on cognitive testing while controlling for the above measures on all three imaging modalities. In many cases, model predictability improved with the addition of network-based neuroimaging data to clinical data. We also found our network-based models performed superiorly to the comparison models comprised of only clinical or a Meta ROI score. Creating predictive models from imaging studies at a baseline time point that are agnostic to clinical diagnosis as we have described could prove invaluable in both the clinical and research setting, particularly in the development and implementation of future disease modifying therapies.
Scopolamine transdermal system is designed for continuous release of scopolamine following application to an area of intact skin on the head, behind the ear. Each system contains 1.5 mg of scopolamine base. Scopolamine is (αS)-α-(hydroxymethyl)benzeneacetic acid (1α,2β,4β,5α,7β)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]non-7-yl ester. The molecular formula is C17H21NO4 and its structural formula is:

Scopolamine has a molecular weight of 303.35 and a pKa of 7.55-7.81. The scopolamine transdermal system is a circular, 1.8 cm2 film with four layers. Proceeding from the visible surface towards the surface attached to the skin, these layers are: (1) a backing layer of peach-colored polyethylene/polyester film printed with brown ink; (2) a solid matrix drug reservoir layer of silicone adhesive, scopolamine and povidone; (3) a microporous polypropylene membrane; and (4) an adhesive formulation of silicone adhesive, povidone and scopolamine. A protective, oversized release liner of fluoropolymer-coated polyester, which covers the adhesive formulation layer, is removed before the system is used. The brown ink contains acrylic polymers, carbon black, iron oxides (red and yellow), polydimethylsiloxane, polyethylene wax, polytetrafluoroethylene, polyvinylpyrrolidone, sodium dioctyl sulfosuccinate and triethanolamine.

Scopolamine transdermal systems are packaged with an additional piece of protective film covering the system within each pouch. This piece of protective film is removed and discarded at the time of use.

Cross section of the system:
The present invention addresses the problem of providing a novel anti-CD147 antibody having exceptional anti-tumor activity and exceptional safety. The present invention also addresses the problem of providing a medicine containing such an antibody. The present invention also addresses the problem of providing, inter alia, a method for treating tumors in which the antibody or medicine is used. The present invention provides a CD147-specific antibody that activates CD147 and demonstrates a strong anti-tumor effect. The present invention provides an anti-CD147 antibody that demonstrates a strong anti-tumor effect independent of effector function. The present invention provides a pharmaceutical composition that contains such an anti-CD147 antibody. The present invention provides a method for treating tumors in which such an anti-CD147 antibody and/or pharmaceutical composition is used.
A computerized medical diagnostic system uses a training dataset that is updated based on reports generated by a radiologist. AI and/or CAD is used to make an initial determination of no finding, finding, or diagnosis based on the training dataset. Normal results with a high confidence of no finding are not reviewed by the radiologist. Low confidence results, findings, and diagnosis are reviewed by the radiologist. The radiologist generates a report that associates terminology and weighting with marked 3D image volumes. The report is used to update the training dataset.
At the TTMPB group, the block will be performed by the surgeon before the closure of the sternum by visualizing the muscles and identifying them. In the TTMPB group patients will receive 40 ml %0.375 bupivacaine divided into 4 equal doses between internal intercostal muscle and transversus thoracic muscle at the 2nd and 3rd intercostal space and 4th and 5th intercostal space.
PURPOSE: Marginal ulceration (MU) following Roux-en-Y gastric bypass (RYGB) is an established complication, with early MU (within 30-days of operation) being less understood compared to its late counterpart. This study aims to identify risk factors for early MU in patients undergoing primary RYGB.
METHODS: Utilizing data from the Metabolic and Bariatric Surgery Accreditation Quality Improvement Project (MBSAQIP 2015-2021), 1,346,468 records were evaluated. After exclusions for revisions, conversions, pediatric cases, nonbinary gender, missing body mass index (BMI) data, and missing operative time; 291,625 cases of primary RYGB were included for full analysis and rare events modeling of early MU.
RESULTS: The prevalence of early MU was .29% (n = 850). Higher rates of early MU were associated with BMI, race, history of diabetes mellitus (DM), prior thrombotic complications (deep vein thrombosis (DVT) and pulmonary embolism (PE)), prior percutaneous cardiac intervention (PTC), immunosuppressive therapy, and anticoagulation status. Additionally, procedural aspects like the nonspecialization of the surgeon and longer operative times also correlated with higher early MU rates. Rare-events regression modeling noted significant associations of early MU with younger age, diabetes requiring insulin, history of PTC, DVT, immunosuppressive therapy, and anticoagulation status.
CONCLUSION: Early MU remains a relatively rare complication. The lower than previously reported occurrence suggests possible improvements in both patient preparation and surgical technique. The identification of relevant risk factors enables better perioperative and intraoperative management of patients at risk of developing early MU.
The open placebo will consist of typical prescription medicine bottle of placebo pills with a label clearly marked "placebo pills" "take 2 pills twice daily." The placebo pills are made from Microcrystalline Cellulose.
Parallel to the increase in life expectancy by years, the population of women living in the post-menopausal period is also increasing. In order to have a healthy menopause, which is an important part of women's life, it is thought that the distant reiki without health risks by women may be effective in reducing the symptoms of menopause experienced by women. In line with this information, it was aimed to determine the effect of distant reiki on menopausal symptoms. The study was carried out with menopausal women between the ages of 40-55 in Adana province in Turkey. Therefore, in the study, 48 women in the menopausal period between the ages of 40-55 was randomly assigned to reiki and control groups. Distant reiki application for 30 minutes three times a week for four weeks was applied individually to the study group. No intervention was made to the control group for a period of four weeks. The primary expected outcome of the research is the effect of distant reiki on menopausal symptoms of menopausal women. Results was applied three times in total, before the study and control application, 4 weeks and 8 weeks later.
PROBLEM TO BE SOLVED: To obtain the subject therapeutic agent capable of checking pruritus, moderating the keratinizing tendency of a horny layer, suppressing the propagation of bacteria and fungi and manifesting effects on atopic dermatitis without any adverse effects by including several ingredients having pharmacodynamic effects and converting the resultant agent into an ointment. SOLUTION: This therapeutic agent for dermatosis is obtained by including (A) acetylcholine chloride, (B) caffeine and sodium benzoate, (C) oxytetracycline hydrochloride and (D) trichomycin and converting the resultant agent into an ointment. The amounts of the formulated respective ingredients are preferably 25 g of the ingredient A, 25 g of the ingredient B, 1,000 mg of the ingredient C and 500,000 units of the ingredient D. Furthermore, (E) 250 mg of chloramphenicol is preferred. The ingredient A is capable of removing pruritus of skin and the ingredient B is capable of softening a horny layer of the skin and facilitating the peeling of the horny layer. The ingredient C is effective against staphylococci, streptococci, Escherichia coli, or the like, and the ingredient D is effective against fungi.  The ingredient E is effective against the staphylococci, Escherichia coli, or the like. Atopic dermatitis is effectively treated by pharmacodynamic effects of the formulated respective ingredients.